Canada markets open in 5 hours 8 minutes

Biofrontera Inc. (BFRI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8000+0.1900 (+7.28%)
At close: 04:00PM EDT
2.8000 0.00 (0.00%)
After hours: 06:51PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.6100
Bid0.0000 x 1000
Ask0.0000 x 1800
Day's Range2.5600 - 2.8000
52 Week Range2.2000 - 14.6300
Avg. Volume1,879,101
Market Cap47.893M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.5900
Earnings DateApr 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.50
  • GlobeNewswire

    Biofrontera Inc. Announces Closing of $9.4 Million Private Placement

    WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the closing of its previously-announced $9.4 million private placement with a single institutional investor. “This private placement allows us to continue executing on our aggressive growth plan. Proceeds from the fundraise will primarily be used to fund our commercial strategy including our near-term object

  • GlobeNewswire

    Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement

    WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 3,419,000 shares of common stock, in a private placement. The purchase price for one share of common stock (or common stock equivalent) and a warrant to

  • GlobeNewswire

    Biofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update

    Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three months ended March 31, 2022, and provided a business update. Financial Highlights & Recent News Total revenues for the first quarter of 2022 were $9.8 million, an increase of 106% from the first quarter of